MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

2095 Selected Articles from This Issue

EDITORIAL

2097 Twentieth Anniversary of Molecular Cancer Therapeutics: A Vision for the Future
Beverly A. Teicher

MCT FIRST DISCLOSURES

2098 Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D. Smith, Michael D. Kaufman, Scott C. Wise, Yu Mi Ahn, Timothy M. Caldwell, Cynthia B. Leary, Wei-Ping Lu, Gege Tan, Lakshminarayana Vogeti, Subha Vogeti, Breelyn A. Wilky, Lara E. Davis, Maitreyi Sharma, Rodrigo Ruiz-Soto, and Daniel L. Flynn

2110 A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer

REVIEW

2117 Synthetic Lethality in Ovarian Cancer
Akshaya Chandrasekaran and Kevin M. Elias

SMALL MOLECULE THERAPEUTICS

2129 ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts
Andrew M. Baschnagel, Jacob H. Elnaggar, Haley J. VanBeek, Ashley C. Kromke, Justin H. Skiba, Saakshi Kaushik, Lindsey Abel, Paul A. Clark, Colin A. Longhurst, Kwanugok P. Nickel, Ticiana A. Leal, Shuang G. Zhao, and Randall J. Kimple

2140 CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition

2151 SLFN11 Is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents

2166 The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria

2177 Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Paul Rossman, Tanja S. Zabka, Audrey Ruple, Dietrich Tuerck, José A. Ramos-Vara, Liling Liu, Rodrigo Mohalem, Mark Merchant, Jackeline Franco, Christopher M. Fulkerson, Ketaki P. Bhide, Matthew Breen, Uma K. Aryal, Elaine Murray, Noel Dybdal, Sagar M. Utturkar, Lindsey M. Fourez, Alexander W. Enstrom, Deepika Dhawan, and Deborah W. Knapp
# Table of Contents

2189 Translational Strategies for Repotrectinib in Neuroblastoma

2198 The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation
Yuchen Jiang, Xia Peng, Yinchun Ji, Yang Dai, Yanfen Fang, Bing Xiong, Wenming Ren, Youhong Hu, Yi Chen, and Jing Ai

2207 Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-Positive AML
Megan E. Zavorka Thomas, Xiyuan Lu, Zahra Talebi, Jae Yoon Jeon, Daelynn R. Budlow, Alice A. Gibson, Muhammad Erfan Uddin, Lindsay T. Brinton, Julie Nguyen, Meghan Collins, Alessia Lodi, Shannon R. Sweeney, Moray J. Campbell, Douglas H. Sweet, Alex Sparreboom, Rosa Lapolombella, Stefano Tiziani, and Sharyn D. Baker

2218 LARGE MOLECULE THERAPEUTICS
NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo

2228 Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
Samantha Buongervino, Maria V. Lane, Emily Garrigan, Doncho V. Zhelev, Dimiter S. Dimitrov, and Kristopher R. Bosse

2240 Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastrectic Cancers
Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villafior, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, and John H. Strickler

2250 A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
Melanie Wurm, Otmar Schaaf, Katharina Reutner, Rajkumar Ganesan, Sven Mostböck, Christina Pelster, Jark Böttcher, Bruna de Andrade Pereira, Christina Taubert, Isabella Alt, Garazi Serna, Aurelie Auguste, Kai B. Stadermann, Denis Delic, Fei Han, Jaume Capdevila, Paolo G. Nuciforo, Rachel Kroe-Barrett, Paul J. Adam, Anne B. Vogt, and Irmgard Hofmann

2262 Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models
Takuya Kato, Ryohei Okada, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Hiroshi Fukushima, Peter L. Choyke, and Hisataka Kobayashi

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS
2274 Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible

TARGETING DRUG RESISTANCE
2280 Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Austin R. Dosch, Samara Singh, Xi Zi Dai, Siddharth Mehra, Iago De Castro Silva, Anna Bianchi, Supriya Srinivasan, Zhen Gao, Yuguang Ban, Xi Chen, Sulagna Banerjee, Nagaraj S. Nagathihalli, Jashodeep Datta, and Nipun B. Merchant

MODELS AND TECHNOLOGIES
2291 Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Alison R. Mercur-Smith, Wilun Jiang, Juli R. Bago, Alain Valdivia, Morrent Thang, Alex S. Woodell, Stephanie A. Montgomery, Kevin T. Sheets, Carey K. Anders, and Shawn D. Hingtgen

2302 SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy
Yajing Zhang, Xiaohong Yu, Qiuping Liu, Haiping Gong, An-an Chen, Hongjun Zheng, Shi Zhong, and Yi Li
Vimseltinib is a colony stimulating factor 1 receptor (CSF1R) inhibitor that acts to block both autocrine signaling in tenosynovial giant cell tumor (TGCT) as well as paracrine signaling to inflammatory cells such as macrophages and osteoclasts. Vimseltinib was able to inhibit tumor growth in preclinical models and reduced biomarkers in three initial patients. Read the full study on page 2098.

doi: 10.1158/1535-7163.MCT-20-11-CVR
Molecular Cancer Therapeutics

20 (11)

Mol Cancer Ther 2021;20:2095-2313.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/20/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/20/11.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.